
Algen Biotechnologies
Algen Biotechnologies is a YC Winter 2020 (W20) company. Based in San Francisco, CA, USA. Team of 13.
About Algen Biotechnologies
Summary
Algen Biotechnologies builds a drug discovery platform that combines a proprietary CRISPR gene-modulation system with AI foundation models to map the RNA signaling networks that drive cancer, inflammation, and other high-unmet-need diseases. The platform generates single-cell gene expression data at scale, then uses deep learning to identify which RNA messages cause disease progression, producing high-confidence drug targets. This replaces conventional trial-and-error target identification with a systematic, biology-first approach to finding first-in-class medicines.
Go-to-market
Pharmaceutical and biotech companies are the customers, reached through research partnerships. AstraZeneca is a confirmed partner, engaging Algen Biotechnologies through a collaboration deal rather than a product purchase.
From the Y Combinator listing
Using CRISPR to find treatments for cancer and inflammation
Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 13
- Active
- Early
Founders (2)
- Christine Du
- Chun-Hao Huang
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works